HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Details Dished On Regulatory Pathway US FDA’s Developing For Lawful Hemp In Supplements

Executive Summary

Pathway separate from FDA’s regulation of drugs and food would include rules on content limits, labeling, disclosure of ingredients– including assurances of no contaminants, and requirements to mitigate accidental ingestion.

You may also be interested in...



Industry Looking For Details As Legislation Looks Likely On Hemp Ingredients' Use In Supplements

Whether lawmakers will favor legislation aligning with FDA’s thinking or hemp industry’s preferences isn’t known, says Jonathan Miller, US Hemp Roundtable general counsel. “We're feeling pretty confident that something's going to happen.”

Bill Steering Hemp In Supplements To NDI Notification Pathway Introduced For Third Time

Virginia Republican Morgan Griffith has same message for FDA he’s previously stated about hemp ingredients. Agency “has dragged its feet in properly regulating CBD and hemp-derived products on the market, creating confusion about its legal uses,” he says.

US FDA Doubts Hemp ‘Derivatives Created From Scratch’ Belong In Lawful Use Pathway

States’ histories with legalizing cannabis aren’t good models for an hemp regulatory pathway, says FDA hemp and cannabis policy chief Norman Birenbaum. Influence from those models already seen in US with ingredients including delta-8 THC marketed as hemp as defined in federal law de-scheduling it as a controlled substance.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel